Global Cancer Technology

Global Cancer Technology

About this raise

Global Cancer Technology, with a post-money valuation of $11.6 million, is raising funds on NetCapital. It is an emerging medical technology company that may soon revolutionize cancer therapy. The technology of Global Cancer Technology is protected by several patents and is aimed at remote-controlled cancer drug delivery. Global Cancer Technology was founded by John P. Clark. The current round of crowdfunding has a minimum target of $10,000 and a maximum target of $107,000, and the proceeds will be used for pre-clinical work, research, marketing, commercialization, and general and administrative expenses. The technology of Global Cancer Technology was developed by scientists at Moores Cancer Center UC San Diego. Using the technology, the cancer drug will be attached to a nanocrystal scintillator and delivered to the body conveniently.

Expand

Investment Overview

Invested this round: $107,000

Deal Terms

Total Commitments ($USD)

Platform
Netcapital
Start Date
10/22/2019
Close Date
02/25/2020
Min. Goal
$10,000
Max Goal
$107,000
Min. Investment

$1

Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$11,571,400

Company & Team

Company

Year Founded
2017
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Location
San Diego, California
Company Website
Visit Website

Team

Employees
1

Financials

Financials are not currently available for this company. This may occur if the company is still Testing the Waters, is a Regulation D offering, or if the financials are still under review and being confirmed by our team. For Reg CF and Reg A+ raises, please check back later.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/29/2022 Netcapital $26,682,636 $0 Equity - Common Not Funded RegCF
09/08/2021 Dalmore Group - $24,400 Equity - Common Funded RegA+
02/25/2020 Netcapital $11,571,400 $107,000 Equity - Common Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Global Cancer Technology on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $11,571,400
Price per Share: $1.00

Follow company

Follow Global Cancer Technology on Netcapital

Buy Global Cancer Technology's Deal Report

Warning: according to the close date for this deal, Global Cancer Technology may no longer be accepting investments.

Global Cancer Technology Deal Report

Get Kingscrowd's comprehensive report on Global Cancer Technology including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Global Cancer Technology is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Global Cancer Technology deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge